Press Releases for MDCO

Press Releases
RidgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on LGF, AZ, MW, R, MDCO and LPNT
The Medicines Company Announces New Patent Issuance for Angiomax(R)
The Medicines Company Withdraws European Marketing Application for 3-7 Day Daily Dose Oritavancin Therapy
The Medicines Company Announces Option Grants Under Nasdaq Marketplace Rule 5635
The Medicines Company Responds to Incorrect News Reports
The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635
The Medicines Company Reports Second Quarter 2009 Financial Results
The Medicines Company Appoints T. Scott Johnson as Vice President, New Business Ventures & Chief Medical Advisor
The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635
The Medicines Company to Announce Second Quarter 2009 Financial Results on Wednesday, July 29, 2009
The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635
FDA Grants The Medicines Company Pediatric Exclusivity for Angiomax(R)
The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635
The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 4350
The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 4350
The Medicines Company to Participate in the Deutsche Bank Health Care Conference
The Medicines Company Discontinues Phase 3 CHAMPION Clinical Trial Program of Cangrelor
Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
The Medicines Company Announces Option Grants Under Nasdaq Marketplace Rule 4350
The Medicines Company Reports First Quarter 2009 Financial Results
The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 4350
The Medicines Company to Announce First Quarter 2009 Financial Results on Wednesday, April 29, 2009
The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 4350 - Apr 2 2009 5:39PM
The Medicines Company EU Filing Accepted for Cleviprex(R) for the Treatment of Acute Hypertension
The Medicines Company Completes Acquisition of Targanta Therapeutics Corporation
The Medicines Company Announces Completion of Tender Offer for Shares of Targanta Therapeutics
The Medicines Company Reports Full Year and Fourth Quarter 2008 Financial Results
The Medicines Company to Announce Fourth Quarter and Full Year 2008 Financial Results on Wednesday, February 18, 2009
The Medicines Company Commences Tender Offer for All Outstanding Shares of Targanta Therapeutics
Zacks Analyst Blog Highlights: PartnerRe Ltd., The Medicines Company, Targanta, Petroleum Development and WellPoint, Inc.
The Medicines Company to Acquire Targanta Therapeutics
The Medicines Company to Participate in the 27th Annual JP Morgan Healthcare Conference
Zacks Bull and Bear of the Day Highlights: The Medicines Co., CRA International, Bank of America, Wells Fargo and Citigroup
NASDAQ OMX and Leerink Swann to Co-Host HealthCare Industry Forum - Dec 4 2008 9:39AM
New Publication Shows Angiomax Significantly Reduces Initial Hospital Costs by $572 Per Patient Compared to Conventional Therapy in Moderate and High-Risk ACS Patients
The Medicines Company Reports Third Quarter 2008 Financial Results
Poor Perioperative Blood Pressure Control Linked to 30-Day Morbidity and Mortality in Cardiac Surgery Patients
Angiomax(R) Reduced Cardiac Mortality by 43 Percent and Improved Overall Survival by 31 Percent at One-Year in HORIZONS-AMI Trial
HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients
The Medicines Company Announces HORIZONS-AMI 1-Year Data To Be Presented at 2008 TCT Meeting
The Medicines Company to Announce Third Quarter 2008 Financial Results on Wednesday, October 22, 2008
New Publication Shows Cleviprex(TM) Provides More Precise Blood Pressure Control in Cardiac Surgery Patients
New Analysis From HORIZONS-AMI Shows Major Bleeding Has a Significant Impact and Contributes to 30-Day Mortality Following Angioplasty in Severe Heart Attack Patients
ACUITY 1-Year Sub-Analysis Published in Journal of the American College of Cardiology
New Publication Shows Cleviprex(TM) is Safe and Effective for Treatment of Acute, Severe Hypertension
TVM Capital Welcomes The Medicines Company in The European Market Through the Acquisition of Curacyte Discovery GmbH
The Medicines Company Acquires CU-2010 and Curacyte Discovery GmbH
Curacyte Sells Its Subsidiary Curacyte Discovery GmbH to The Medicines Company
The Medicines Company's Cleviprex(TM) Receives FDA Approval
The Medicines Company Reports Second Quarter and First Half 2008 Financial Results and Raises Full Year Top Line Guidance
New Publication Shows Cleviprex(TM) is Effective for Rapid Treatment of Acute Hypertension After Cardiac Surgery
The Medicines Company to Announce Second Quarter 2008 Financial Results on Wednesday, July 23, 2008
Controlling Perioperative Hypertension with Cleviprex Reduces Risk of Heart Attack and of Death Following Cardiac Surgery, According to New Analyses
The Medicines Company Hires Glyn R. Parkin as Senior Vice President, International Operations
The Medicines Company to Participate in the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
The Medicines Company Announces Option Grants under NASDAQ Marketplace Rule 4350 - Jun 3 2008 5:11PM
Cleviprex(TM) Reduces and Controls Acutely Elevated Blood Pressure in Elderly Patients, According to New Analysis from VELOCITY Trial
The Medicines Company Receives FDA Review Letter for Angiomax Supplemental Filing
Results Published in New England Journal of Medicine Show Angiomax Improved Net Clinical Outcomes and Resulted in Improved Survival Rates in the Most Severe Heart Attack Patients - May 27 2008 1:01AM
The Medicines Company Announces Option Grants under NASDAQ Marketplace Rule 4350 - May 27 2008 12:54AM
Results Published in JACC Show Clinical Advantage of Switching to Angiomax from Heparin in Acute Coronary Syndrome Patients Undergoing Early Invasive Treatment - Jun 2 2008 12:55AM
The Medicines Company Announces Option Grants under NASDAQ Marketplace Rule 4350 - Jun 2 2008 12:54AM - Business Wire - Jun 2 2008 12:54AM
The Medicines Company Reports First Quarter 2008 Financial Results
The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 4350 - Jun 2 2008 12:54AM - Business Wire - Jun 2 2008 12:54AM
The Medicines Company to Announce First Quarter 2008 Financial Results on Wednesday, April 23, 2008